O5 Hepatitis C elimination in HIV/HCV co-infection through HCV treatment in primary care is feasible and highly effective

by J.S. Doyle, A.L. Bowring, J. Cutts, J. Roney, D.M. Iser, J. Sasadeusz, M. O’Reilly, C. Fairley, E. Gane, J. Hoy, G.V. Matthews, N. Medland, R. Moore, M. Prins, M. Stoové, B.K. Tee, M.E. Hellard
Published 2017-08-01

O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study

by G. Dore, J. Grebely, F. Altice, A.H. Litwin, O. Dalgard, E.J. Gane, O. Shibolet, A. Luetkemeyer, R. Nahass, C.Y. Peng, B. Conway, D.M. Iser, H.C. Huang, I.N. Gendrano, M. Kelly, P. Hwang, M. Robertson, J. Wahl, E. Barr, H.L. Platt
Published 2017-08-01